comparemela.com

Latest Breaking News On - Synimmune gmbh - Page 1 : comparemela.com

Xlife Sciences AG Publishes 2023 Annual Report - adhoc - Börsennachrichten

Xlife Sciences AG Key word Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23Apr2024 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is solely responsibl

Germany
United-states
Switzerland
Abu-dhabi
Abuz-aby
United-arab-emirates
Synimmune-gmb
Oliverr-baumann
Xlife-group
European-patent-office
Axenoll-life-sciences

Xlife Sciences AG Publishes 2023 Annual Report

Xlife Sciences AG / Key word: Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The.

Abu-dhabi
Abuz-aby
United-arab-emirates
United-states
Germany
Switzerland
Oliverr-baumann
Synimmune-gmb
European-patent-office
Xlife-sciences
Axenoll-life-sciences

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

Xlife Sciences AG / Key word: Mergers & Acquisitions/Takeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29-Dec-2023 / 17:45 CET/CEST Release of an ad hoc.

Christoph-antz
Oliverr-baumann
Synimmune-gmb
Xlife-sciences
Synimmune-gmbh
Acute-myeloid-leukemia
Acute-myeloid
Shareholders-meeting
Year-report
Markets

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline - adhoc - Börsennachrichten

Xlife Sciences AG Key word Mergers & AcquisitionsTakeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29Dec2023 1745 CETCEST Release of an ad hoc announcement pursuant to

Synimmune-gmb
Christoph-antz
Oliverr-baumann
Xlife-sciences
Synimmune-gmbh
Acute-myeloid-leukemia
Acute-myeloid
Shareholders-meeting
Year-report
Ouxlife
Ciences
Mergers

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

29.12.2023 - Xlife Sciences AG / Key word(s): Mergers & Acquisitions/Takeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29-Dec-2023 / 17:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely . Seite 1

Synimmune-gmb
Xlife-sciences
Synimmune-gmbh

vimarsana © 2020. All Rights Reserved.